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1. Introduction 
The in vitro diagnosis of allergic reactions to drugs is of particular interest to clinicians, as 
neither the clinical history nor the in vivo tests are fully conclusive. In addition, these tests 
may often be associated with risk, as occurs with the drug provocation test. Various 
different in vitro tests are available for the evaluation of drug hypersensitivity depending on 
the immunological mechanism involved, either IgE mediated or T cell mediated.  
For IgE-mediated reactions, the determination of serum-specific IgE, antigen-specific 
histamine release and sulphidoleukotriene production after in vitro stimulation of effector 
cells, as well as analysis of the activation markers of these cells (the basophil activation test), 
provide greater diagnostic precision. 
Serum-specific IgE assays are still the most common in vitro method for evaluating 
immediate reactions. However, either there is no great commercial availability of fixed drugs 
for this study, with the exception of antibiotics (penicillin G and V, ampicillin, amoxicillin and 
cefaclor), a few muscle relaxants and certain substances, like insulins and ACTH. The most 
validated immunoassay, ImmunoCAP (Phadia, Uppsala, Sweden), has been widely used to 
evaluate immediate reactions to beta-lactams, mainly penicillins, with a specificity 
approaching 90% and a sensitivity of up to 50% (Blanca et al., 2001; Sanz et al., 2002a) 
The in vitro study of the cell response in non-immediate reactions mainly assesses the T-cell 
response. A cellular response involving drug-related T-cell activity may be assessed in vitro 
by means of both the lymphocyte transformation test (LTT) (Pichler & Tilch, 2004) and the 
flow cytometric lymphocyte activation test, based on upregulation of the activation marker 
CD69 (Beeler et al., 2008). The combination of these tests with an assay of the production of 
drug-specific cytokines (e.g., IFN-g, IL-2, IL-5, IL-8 and IL-12) can increase the sensitivity 
and specificity to 48% and 82%, respectively (Romano et al., 2011; Rozieres et al., 2009a). 
2. Cellular tests for the diagnosis of immediate type drug hypersensitivity 
reactions 
2.1 The Basophil activation test 
The in vitro diagnosis of drug allergies has advanced much over recent years, mainly due to 
the incorporation of new technologies, such as flow cytometry, which permits the analysis 
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of various types of cells, even when they are poorly represented in peripheral blood, as is 
the case with basophils. These cells are a useful model for the study of IgE-mediated 
reactions, as they are effectors of the reactions (Schleimer et al., 1985). 
Basophils are able to release the content of their granules (either preformed mediators, like 
histamine, or formed de novo, like sulphidoleukotrienes) after antigen-specific activation. In 
addition, after this process they express, or overexpress, activation molecules on their 
membranes (Fig. 1). 
 
 
Fig. 1. Immune response in Immediate drug allergic reaction. 
The basophil activation test (BAT) is based on the identification of basophils by labelling 
with monoclonal antibodies against different molecules, such as the IgE receptor, anti-CD 
123 (IL-3 receptor) and fluorochrome-labelled anti-HLA-DR or anti-CCR3. This strategy, 
coupled with the identification of cell activation markers, such as CD63 or CD 203c, enables 
the comparison of cell activation before and after in vitro antigen-specific stimulation (Sanz 
et al., 2002b). Parallel to this process there is production of mediators, such as 
sulphidoleukotrienes that can be quantified simultaneously. 
The CD63 molecule is a tetraspan, 53 kDa granular protein that is expressed not only on 
basophil granules but also on monocytes, macrophages and platelets. The expression of this 
marker correlates with degranulation and histamine release, which makes it an ideal marker 
of basophil activation (De Weck et al., 2008). 
For in vitro stimulation with allergen, the peripheral blood cells are incubated with the 
suspected allergen for 15-40 minutes at 37ºC (Fig. 2).  
After stopping the reaction, the cells are labelled with anti-CD63-PE and anti-IgE-FITC 
monoclonal antibodies. Two controls are used: a negative control in which the cells are 
incubated with the stimulation buffer used in the assay and that often contains IL-3 
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(negative control alias basal stimulation); as a positive control, an anti-IgE or an anti-IgE 
receptor antibody can be used (Sanz et al., 2008) (Fig. 3). The results are analised through 
flow cytometry (Fig. 4). 
 
 
Fig. 2. Basophil activation test. Stimulation phase. 
 
Fig. 3. Basophil activation test. Labelling phase. 
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Fig. 4. Flow cytometry analysis. 
Numerous studies over recent years have shown the usefulness of this technique for the in 
vitro diagnosis of allergic diseases (Ebo et al., 2006a, 2004a; Kleine-Tebbe et al., 2006) 
involving different allergens, such as inhalants (Paris-Köhler et al., 2000; Sanz et al., 2001; 
Saporta et al., 2001), hymenoptera venoms (Sabbah et al., 1998; Sainte-Laudy et al., 2000), or 
latex (Ebo et al., 2002; Sanz et al., 2003). For the diagnosis of allergy to drugs like muscle 
relaxants (Abuaf et al., 1999; Monneret et al., 2002), betalactam antibiotics (Sanz et al., 2001b, 
2002a; Torres et al., 2004), pyrazolones (Sabbah et al., 1997; Sanz et al., 2005) and non 
steroidal anti-inflammatory drugs (NSAIDs) (Gamboa et al., 2004) BAT has opened up an 
important diagnostic pathway, either on its own or combined with other techniques (de 
Weck et al., 2008b; Gamboa et al., 2003a), allowing avoidance of challenge tests in an 
important number of cases (Hausmann et al., 2009; Romano et al., 2011; Sanz et al., 2009). 
2.1.1 Basophil activation test and sulphidoleukotriene production in immediate type 
allergic reactions to beta-lactams 
We studied the reliability of BAT, the determination of specific IgE by CAP (CAP-FEIA, 
Phadia, Uppsala, Sweden) and the production of leukotrienes after antigen-specific 
stimulation using the Cellular Antigen Stimulation Test (CAST ELISA (Bühlmann 
Laboratories, Allschwill, Switzerland) for the in vitro diagnosis of immediate allergy to 
betalactams in a series of 81 patients (58 patients with positive and 23 with negative skin 
tests) and in 30 healthy controls (Gamboa et al., 2004b; Sanz et al., 2001b, 2002a). Our results, 
as well as those found by Torres et al (Torres et al., 2004), showed that the sensitivity of BAT 
in the diagnosis of immediate hypersensitivity reactions to beta-lactams was 50%, and the 
specificity 93.3%, although there were certain differences depending on the technique 
applied (e.g., use of total blood or isolated cells) (de Weck et al., 2008a). 
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In our study (Sanz et al., 2002a) the best predictive values were obtained with BAT, in 
comparison with immunoassay or CAST. The positive predictive value of BAT was 18.9% 
and the negative predictive value 97.7%, with amoxicillin being the antibiotic with the 
highest predictive values. The joint use of CAP (Phadia) and BAT allowed identification of 
65.2% of the betalactam allergic patients, with a specificity of 83.3% (Sanz et al., 2008).  
In betalactam allergic patients with negative skin tests BAT was positive in 39.1%, CAST 
was positive in 22.7% with a specificity of 83.3%, and CAP showed a sensitivity of 21.7% 
with a specificity of 83.3%. The association of all three techniques allowed diagnosis in 
60.9% of the patients of this group, with a specificity of 70% (Gamboa et al., 2004b). 
Torres et al (Torres et al., 2004) studied the reliability of BAT in 70 patients with immediate 
allergic reactions. Like us, these authors found a greater positivity to amoxicillin (28.6%), 
followed by benzylpenicillin (BP) (21.7%), penicilloyl polylysine (PPL) (20%), ampicillin 
(12.5%) and MDM (2.2%).  
They, too, reported a BAT sensitivity for cephalosporins of 77.7%. These results have since 
been confirmed in a multicentre study involving 181 betalactam allergic patients and 80 
controls. This study concluded that the association of this technique with the determination 
of the production of antigen-specific sulphidoleukotrienes increases the sensitivity to 62% 
(de Weck et al., 2008b). 
A certain lack of association exists between clinical and BAT cross-reactivity, which restricts 
the usefulness of this method for predicting cross-reactive responses in beta-lactam 
reactions. With BAT it is possible to find positive results when BP is used as the hapten in 
patients who are selective responders to amoxicillin (Torres et al., 2004).  
2.1.2 BAT in IgE-mediated hypersensitivity reactions to quinolones 
IgE-mediated hypersensitivity reactions to quinolones are a particularly difficult situation 
for the clinician as skin testing may induce false positive results. A recent report confirms 
that BAT is a useful method for diagnosing patients with confirmed immediate allergic 
reactions to quinolones (Aranda et al., 2011). In this study, involving 38 patients, the 
Sepharose-RIA technique was positive in 12 cases (31.57%), BAT in 27 (71.05%) and the 
combination of both tests showed positive results in 28 (73.68%). The drug most frequently 
involved in the reaction was moxifloxacin (63.2%), followed by ciprofloxacin (28.9%). The 
authors conclude that the BAT is a useful method for diagnosing patients, especially in 
those with severe reactions where drug provocation testing may increase the risk. 
2.1.3 Basophil activation test in muscle relaxant allergic reactions 
Muscle relaxants are an important group of drugs involved in 60% of adverse reactions 
during anaesthesia. Relevant studies have found that BAT sensitivity and specificity for 
muscle relaxants varied from 36% to 92% and 93% to 100%, respectively (Sudheer et al., 
2005). Most of these studies reported a high specificity and a sensitivity above 50%, reaching 
91% (Abuaf et al., 1999; Kvedariene et al., 2006; Laxenaire et al., 1999; Monneret et al., 2002; 
Moss, 1995; Stellato et al., 1991). 
This sensitivity is lower (36%) when the marker CD203c is used (Sudheer et al., 2005). 
However, results are discordant; Kvedarine et al. (Kvedariene et al., 2006) observed in 47 
patients a sensitivity of 36% and a specificity of 93% performing BAT (CD63 in whole 
blood). On the other hand, Ebo et al. (Ebo et al., 2006b) reported the sensitivity of a similar 
BAT technique to be 91.7% and the specificity 100% for rocuronium in a study including 14 
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patients with an anaphylactic reaction to drugs and with a positive skin test to rocuronium. 
However, the sensitivity apparently increases up to 80% when BAT is performed shortly 
after the clinical reaction (Kvedariene et al., 2006); this technique allows evaluation of the 
cross-reactivity between different muscle relaxants (Ebo et al., 2006b).  
Leysen et al (Leysen et al., 2011) recently reported that BAT is complementary to skin testing 
in the assessment of cross-reactivity between rocuronium and vecuronium. In patients with 
negative skin tests and positive sIgE results, BAT helps in interpreting the clinical 
significance of a positive sIgE result. 
These authors found a cross-reactivity with vecuronium in 69% of 104 curarized patients 
with a history of profound hypotension and severe bronchospasm immediately after 
induction of anaesthesia 
2.1.4 Basophil activation test as a diagnostic tool for immediate radiocontrast media 
(RCM) hypersensitivity 
A study involving 26 patients with immediate RCM reactions and 43 specimens from healthy 
volunteers found that the specificity of BAT ranged from 88.4% to 100%, with a sensitivity 
around 50% (most of the patients in this study experienced only mild skin symptoms) 
(Pinnobphun et al., 2011). The authors demonstrated the potential of BAT as a diagnostic tool 
for immediate RCM hypersensitivity, particularly as a confirmation test, with significantly 
higher activated basophil percentages in BAT in patients with a history of immediate RCM 
reactions than in normal controls. The time between the RCM reaction and the BAT in their 
study was rather long (1–4 years), and this time lag may have lowered BAT reactivity. 
2.1.5 Basophil activation test in IgE-mediated selective reactions to NSAIDs 
Until now only two articles have been published on selective NSAID reactors, patients 
reacting exclusively to only one NSAID family through an IgE-mediated mechanism and 
tolerating other NSAID groups (Gamboa et al., 2003a; Gómez et al., 2009). The first study 
comprised 26 patients with exclusive IgE-mediated allergy to methamizole. BAT sensitivity 
was 42.3% and specificity 100%. Upon adding the leukotriene release test, the sensitivity 
increased to 52% in the overall patient group, with a specificity of 92% (Gamboa et al., 
2003a). In the second study, involving 51 patients with immediate reactions also to 
methamizole, the sensitivity was 54.9% but with a lower specificity, 85.71% (Gómez et al., 
2009). The differences in the sensitivities and specificities may have been due to differences 
in the time interval between the in vitro test being performed and the reaction (16.9 versus 8 
months, respectively), and the number of cases with anaphylaxis (57.5% versus 74.5%). 
Importantly, the BAT was positive in 38.5% of patients with negative skin tests but even 
more importantly, the BAT was positive in 75% of patients with anaphylaxis and negative 
skin tests. (Gómez et al., 2009). 
BAT is the only in vitro technique currently available which allows the evaluation, with 
sufficiently high sensitivity and specificity values, of patients with selective IgE-mediated 
reactions to methamizole without the use of drug provocation tests and their associated 
dangers for patients. Negative BAT testing is associated with the delay to the test after the 
occurrence of the reaction. 
2.1.6 Basophil activation test in NSAID hypersensitivity reactions 
The mechanism involved in these type of reactions is not well known although it is clear 
that it is a non immunological mechanism.  
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In this first  study (Gamboa et al., 2004a) in 60 patients with this syndrome the use of only 2 
drugs (aspirin and diclofenac) allowed a diagnosis to be reached in 58% of these patients, with 
a specificity of 90%. In similar studies carried out in 43 patients with NSAID hypersensitivity 
(Rodríguez-Trabado et al., 2008), BAT achieved a sensitivity of 43% with a specificity of 100%.  
Subsequently, the European Network for Drug Allergy began a multi-centre study to validate 
the real usefulness of this technique (de Weck et al., 2010). However, a notable heterogeneous 
response in the results from each participating group in both sensitivity and specificity was 
observed that can be attributed to two main factors: different clinical characteristics in the 
study patients and technical variation between the different groups. The specificity value was 
notably better in those groups that used buffy coat than in those using plasma leukocytes. The 
lower values in sensitivity and specificity found by others increase the need for further studies. 
In this paper (de Weck et al., 2010), we further analyzed basophil activation in vitro in 
apparently normal individuals tolerating the administration of NSAIDs, in particular the 
specificity of these reactions and the role of technical conditions, such as the cell isolation 
technique. Different clinical and technical conditions may give rise to discordant results 
relating to NSAID hypersensitivity reactions (de Weck et al., 2009). 
2.1.7 Basophil activation test in various drug-allergic reactions  
Other drugs are also of interest since evaluation of allergy to drugs that cannot be studied 
by other in vitro techniques is interesting. BAT has proven useful for the in vitro diagnosis 
of such allergy-causing drugs as corticosteroids (Lehmann Ott, 2008), heparins (Caballero & 
Fernández-Benítez, 2003; Ebo et al., 2004b), omeprazole (Gamboa et al., 2003b), cyclosporine 
(Ebo et al., 2001), Gelofusine (Apostolou et al., 2006), dexchlorpheniramine (Caceres Calle & 
Fernández-Benítez, 2004), chlorhexidine (Ebo et al., 2006c), iodinated povidone (Le Pabic et 
al., 2003), hyaluronidase (Ebo et al., 2005), or bovine serum albumin (Orta et al., 2003).  
2.1.8 The sensitivity of BAT for evaluating immediate allergic reactions to drugs may 
decrease over time 
The diagnostic capacity of BAT has been shown to fall as the time increases between the 
clinical reaction and the test, both for allergic reactions to betalactams (where the sensitivity 
of BAT decreases to 12.5% one year after the reaction) (Blanca et al., 1999), and for reactions 
to muscle relaxants, where the sensitivity fell from 85.7% to 47.6% 4-8 years after the 
reaction (Abuaf et al., 1999) as well as for allergy to dipyrone, where 60% of the patients had 
a negative BAT 6 months after the reaction (Gómez et al., 2009), or expressed another way, if 
the tests are carried out within 6 months from the initial drug reaction, the efficacy of the 
BAT increases to 56% (Gamboa et al., 2003a). Thus, it is generally recommended to perform 
BAT at least two weeks after the allergic reaction but within no more than 6 months 
(Rodríguez Trabado et al., 2006), given that negativization of BAT does not correlate with 
tolerance to the drug (Antúnez et al, 2006).  
In summary, BAT is a useful technique for the diagnosis of allergy to drugs, though 
additional validation studies are warranted. 
3. Cellular tests in the diagnosis of non-immediate type drug hypersensitivity 
reactions  
Although it has been shown that delayed reactions to drugs are mediated by effector T 
lymphocytes (Fernández et al, 2010) with a Th1 profile, based on the transcription factors 
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involved and with cytokine and chemokine production (Cornejo-Garcia et al., 2007; 
Fernández et al., 2009; Mullen et al., 2001; Rengarajan et al., 2000), an important number of 
heterogeneous clinical manifestations nevertheless indicate that different mechanisms with 
different cell subsets and mediators may be involved (Posadas et al., 2002) (Fig. 5). 
3.1 Lymphocyte transformation test 
Among the in vitro tests proposed for delayed hypersensitivity reactions to drugs, the 
lymphocyte transformation test (LTT) was one of the earliest. However, for some years now 
its role in the evaluation of these reactions has been questioned. This is owing to the 
existence of studies reporting series with a low number of cases where many drugs were 
involved and the clinical entities experienced by the patients were very heterogeneous 
(Mayorga et al., 2006; Luque et al., 2001). However, promising results together with the need 
for an in vitro test are now revitalizing its use.  
 
 
Fig. 5. Non immediate drug allergic reactions. Different profiles of T response. 
The LTT enables identification of the drug involved and cross-reactivities, but it is important 
to take into account that a negative LTT does not always indicate the absence of a delayed 
reaction to the drug.  
Different studies have shown the good sensitivity and specificity of the LTT, with 
heterogeneity in the drugs and clinical entities (Luque et al., 2001; Naisbitt et al., 2003a, 
2003b; Nyfeler & Pichler, 1997; Schnyder & Pichler 2000). The most frequent drugs studied 
are beta-lactam antibiotics and anti-epileptics, particularly carbamazepine (Hertl et al., 1993; 
Luque et al., 2001; Mauri-Hellweg et al., 1995; Nyfeler & Pichler, 1997; Tapia et al., 2004; 
Yawalkar et al., 2000). These studies have shown an overall sensitivity of 60-70% for LTT 
(Lerch et al., 2007; Luque et al., 2001; Mauri-Hellweg et al., 1995; Pichler & Tilch, 2004). In 
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the case of beta-lactams, for immediate and non immediate reactions, the sensitivity was 
64.5% and 57.9%, respectively and the specificity was 92.8% (Luque et al., 2001; Pichler & 
Tilch, 2004). In a retrospective analysis of patients with adverse drug reactions, the LTT 
sensitivity was seen to depend also on the drug involved in the reaction (Nyfeler & Pichler, 
1997; Roujeau et al., 1985) and the sensitivity might significantly improve when LTT is 
performed at the optimal time (Kano et al., 2007). This timing could vary depending on the 
clinical manifestations, since it has been shown that LTT should be performed within one 
week for patients with MPE and SJS/TEN whereas 5-8 weeks is optimal for patients with 
DRESS (Kano et al., 2007). 
Recently, a modification of the LTT with inclusion of monocyte derived dendritic cells as 
antigen presenting cells has shown promising results, with higher sensitivity and specificity 
in delayed reactions to amoxicillin, heparins, glucocorticosteroids and contrast media, as 
well as providing the possibility of detecting a response over a longer period of time, 
preserving sensitivity to the culprit drug (Lopez S et al., 2009, 2010; Nyfeler & Pichler, 1997; 
Rodríguez-Pena et al., 2006).  
3.2 ELISPOT 
The Elispot assay is based on the detection of a cytokine caught by an immobilized antibody 
and revealed by a secondary antibody (Czerkinsky et al., 1988). With this method it is 
possible to detect different cytokines as well as cytotoxic markers released by antigen or 
drug stimulated cells (Beeler et al., 2006, 2008; Rozieres et al., 2009a; Zawodniak et al., 2010). 
This test has a high sensitivity, and is able to detect fewer than 25 secreting cells per million 
PBMC (Schmittel et al., 1997, 2001). The results are expressed as spot forming cells obtained 
from the rate between the cytokine secretion produced in the presence of the drug compared 
to the absence of stimulus. The Elispot assay has detected lymphocytes secreting cytokines 
such as IFN-, IL-5, IL-13 from allergic patients in the presence of the culprit drug. Recently, 
this test has been used to determine the release of the granule content (granzymes and 
perforin) by cytotoxic cells after activation with the culprit drug (Zawodniak et al, 2010). 
The test showed a high sensitivity and specificity, although in some cases no correlation 
with LTT results was found, probably because cytotoxicity-based tests measure effector cell 
function, which is distinct from proliferative response.  
The secretion of cytokines (IFN-γ) or cytotoxic granules (Granzyme B) has been detected in 
vitro in response to the culprit drug in allergic patients but not in tolerant subjects (Rozieres 
et al., 2009a; Zawodniak et al., 2010), demonstrating that the Elispot can be a complementary 
method to evaluate delayed reactions to drugs. 
3.3 Monitoring delayed reaction to drugs 
Another approach for the in vitro evaluation of delayed reactions to drugs is the follow-up 
of the immunopathological response by performing serial determinations in peripheral 
blood and the affected skin, from the acute phase to basal conditions (Mayorga et al., 2006). 
This enables an idea of the underlying process to be built up, not only in the development 
and progress of the reaction but also related to the degree of response to treatment 
(Mayorga et al., 2003). These reactions involve not only different cell populations but also 
activation markers, signalling molecules, cytokines, chemokines and transcription factors. 
These are all assessed and it is important to determine the changes in the different markers 
rather than their quantification per se.  
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Among the available methods the most widely used are flow cytometry and mRNA gene 
expression by real time PCR. These methodologies provide important information about the 
immunological mechanisms involved, since different clinical manifestations like urticaria, 
MPE, DRESS, AGEP, FDE or TEN are produced by different cell subsets contributing to each 
particular entity. Different authors have shown that CD4+ T lymphocytes are mainly 
involved in MPE, DRESS, and AGEP (Fernandez et al., 2009; 1995; Hertl et al., 1993; Mauri-
Hellweg et al., 1995; Pichler, 2003; Schnyder et al., 2000; Shiora & Muzukawa, 2007; Torres et 
al., 2006, 2009; Whittam et al., 2000; Zedlitz et al., 2002), whereas CD8+ T lymphocytes are 
the effector cells in FDE and TEN (Alanko et al., 1987; Chung et al., 2008; Nassif et al., 2002, 
2004a). Although other studies indicate that both CD4+ and CD8+ T lymphocytes may be 
involved in TEN (Torres et al., 2006) and CD8+ T cells have been found in the epidermis of 
non bullous lesions including MPE (Rozieres et al., 2009b).  
These cells become activated and express high levels of CD25, CD69, CD71 and HLA-DR 
(Leyva et al., 2000; Mayorga et al., 2003; Nishio et al., 2007; Shiohara & Mizukawa, 2007; 
Torres et al., 2008). Apart from activation, different chemokine and chemokine receptors 
involved in cell recruitment to the affected organ, mainly the skin, can also be analyzed. 
Thus, an increase in the expression of cutaneous lymphocyte-associated antigen (CLA), a 
skin homing receptor in delayed reactions to drugs, correlates with disease severity (Blanca 
et al., 2000; Mullen et al., 2001; Torres et al., 2006). In a study in patients with drug-induced 
MPE, an increase in the expression of Th1 chemokines (CXCL9 and CXCL10) and their 
specific receptor CXCR3, as well as in the expression of the cutaneous homing chemokines 
(CCL17, CCL20, and CCL27) and their receptors (CCR4, CCR6, CCR10), with high 
production of TNF-α and IFN-γ, was found at the acute phase of the reaction (Fernandez et 
al., 2008). In MPE or DRESS an increase has also been found in IL-5 and chemokines such as 
RANTES and eotaxins, which explains the involvement of eosinophils expressing CCR3 
(Hertl et al., 1993). In AGEP, another severe delayed drug-induced reaction, lymphocytes 
have a dual role as cytotoxic agents and inducing migration of neutrophils to the skin by 
producing IL-8 (Britschgi & Pichler, 2002; Hertl et al., 1993; Padial et al., 2004; Yawalkar et 
al., 2000). At the acute phase of TEN, T cells are recruited to the skin, producing cytotoxic 
markers such as perforin and granzyme B (Fernandez et al., 2010; Mayorga et al., 2003; 
Pichler, 2003; Posadas et al., 2002; Torres et al., 2006; Zawodniak et al., 2010), and they 
express high levels of CCR10 and their chemokine CCL27 (Tapia et al., 2004).  
As mentioned, this monitoring is useful in order to understand not only the underlying 
mechanisms but also to assess the response to treatment. This latter was analyzed during the 
follow-up of TEN, where the administration of gamma globulin was associated with a rapid 
decrease in the cytotoxic markers (Mayorga et al., 2003). 
A Th1 pattern with expression of IFN-, IL-12, and TNF-α and down-regulation of IL-4 has 
been found in delayed reactions to drugs (Cornejo-Garcia et al., 2007; Posadas et al., 2000). 
The polarizations also extend to the expression of transcription factors, such as T-bet in Th1 
and inhibition of c-maf and GATA3 in Th2 (Cornejo-Garcia et al., 2007). 
3.4 Trafficking between different organs 
Since the skin is the organ most frequently affected in delayed reactions to drugs, it is 
possible to assess the parallel course in the two compartments, the skin (in both biopsies and 
blister fluid cells) and the peripheral blood. At the very early stage of the reaction, there is 
an increase in the blister fluid of CLA+ cells which later appear in peripheral blood, 
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probably due to recirculation from the skin (Leyva et al., 2000; Mayorga et al., 2003). These 
cells also show a Th1 profile, with high production of perforin and granzyme B that 
correlates with the reaction and its severity (Nassif et al., 2004a; 2004b). 
In patients with MPE (Fernandez et al., 2008) an increase in the expression of Th1 
chemokines, including CXCL9 and CXCL10, as well as cutaneous homing chemokines such 
as CCL17, CCL20, and CCL27, was found only in the skin. In this study they also found a 
high production of TNF-α and IFN-γ as well as the presence of Th1 cytotoxic T lymphocytes 
in the skin. However, in the peripheral blood T lymphocytes expressing only the chemokine 
receptors CXCR3, CCR4, CCR6, and CCR10 were found. These data indicate that during the 
reaction there is recruitment of Th1 cytotoxic T lymphocytes to the skin induced by different 
chemokines produced by cutaneous cells (Fernandez et al., 2008). 
4. Acknowledgments 
MLS, PMG and CM are supported by grant RD07/0064 from the Spanish Research Network 
on Adverse Reactions to Allergens and Drugs (RIRAAF: Red de Investigation de Reacciones 
Adversas a Alérgenos y Fármacos) of the Carlos III Health Institute. 
5. References 
Abuaf N., Rajoely B., Ghazouani E., Levy D.A., Pecquet C., Chabane H. & Leynadier F. 
(1999). Validation of flow cytometry assay detecting in vitro basophil activation for 
the diagnosis of muscle relaxant allergy. J Allergy Clin Immunol; 1999; 104: 411-8. 
Alanko T., Stubb S. & Reitamo S. (1987). Topical provocation of fixed drug eruption. Br J 
Dermatol; 1987, 116: 561-567. 
Antúnez C., Fernández T., Blanca-Lopez N., Torres M.J., Mayorga C., Canto G., Fernández 
J., Moya M.C. & Blanca M. (2006) IgE antibodies to betalactams: relationship 
between the triggering hapten and the specificity of the immune response. Allergy; 
61:940-6. 
Apostolou E., Deckert K., Puy R., Sandrini A., de Leon M.P., Douglass J.A., Rolland J.M. & 
O'hehir R.E. (2006) Anaphylaxis to Gelofusine confirmed by in vitro basophil 
activation test: a case series. Anaesthesia; 61:264- 268. 
Aranda A., Mayorga C., Ariza A., Doña I., Rosado A., Blanca-Lopez N., Andreu I. & Torres 
MJ. (2011). In vitro evaluation of IgE-mediated hypersensitivity reactions to 
quinolones. Allergy; 66(2):247-54. 
Beeler A., Engler O., Gerber B.O. & Pichler WJ. (2006). Long-lasting reactivity and high 
frequency of drug-specific T cells after severe systemic drug hypersensitivity 
reactions. J Allergy Clin Immunol; 117:455-462. 
Beeler A., Zaccaria L., Kawabata T., Gerber B.O. & Pichler W.J. (2008) CD69 upregulation on 
T cells as an in vitro marker for delayed-type drug hypersensitivity. Allergy; 63:181-
8. 
Blanca M., Torres M.J., García J.J., Romano A., Mayorga C., de Ramon E., Vega J.M., 
Miranda A. & Juarez C. (1999). Natural evolution of skin test sensitivity in patients 
allergic to beta-lactams. J Allergy Clin Immunol; 103:918-924. 
Blanca M., Posadas S., Torres M.J., Leyva L., Mayorga C., Gonzalez L., Juarez C., Fernandez 
J. & Santamaria L.F. (2000) Expression of the skin-homing receptor in peripheral 
www.intechopen.com
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 272 
blood lymphocytes from subjects with nonimmediate cutaneous allergic drug 
reactions. Allergy; 55:998-1004. 
Blanca M., Mayorga C., Torres M.J., Reche M., Moya M.C., Rodriguez J.L., Romano A. & 
Juarez C. (2001). Clinical evaluation of Pharmacia CAP System RAST FEIA 
amoxicilloyl and benzylpenicilloyl in patients with penicillin allergy. Allergy; 56: 
862–870.  
Britschgi M., Steiner U.C., Schmid S., Depta J.P., Senti G., Bircher A., Burkhart C., Yawalkar 
N. & Pichler W.J. (2001). T- cell involvement in drug-induced acute generalized 
exanthematous pustulosis. J Clin Invest;107(11):1433–41.  
Britschgi M. & Pichler W.J. (2002). Acute generalized exanthematous pustulosis, a clue to 
neutrophil-mediated inflammatory processes orchestrated by T cells. Curr Opin 
Allergy Clin Immunol; 2:325-331.  
Caballero M.R. & Fernandez-Benitez M. (2003). Allergy to heparin: a new in vitro diagnostic 
technique. Allergol Immunopathol; 31:324-328. 
Caceres Calle O, Fernandez-Benitez M. (2004). Allergy to dexchlorpheniramine. Study of a 
case. Allergol Immunopathol; 32: 306-309. 
Chung W.H., Hung S.I., Yang J.Y., Su S.C., Huang S.P., Wei C.Y., Chin S.W., Chiou C.C., 
Chu S.C., Ho H.C., Yang C.H., Lu C.F., Wu J.Y., Liao Y.D., Chen Y.T. (2008). 
Granulysin is a key mediator for disseminated keratinocyte death in Stevens-
Johnson syndrome and toxic epidermal necrolysis. Nat Med; 14:1343-1350.  
Cornejo-Garcia J.A., Fernandez T.D., Torres M.J., Carballo M., Hernan I., Antunez C., Blanca 
M. & Mayorga C. (2007). Differential cytokine and transcription factor expression in 
patients with allergic reactions to drugs. Allergy.;62(12):1429-38. 
Czerkinsky C., Moldoveanu Z., Mestecky J., Nilsson L.A. & Ouchterlony O. (1988). A novel 
two colour ELISPOT assay. I. Simultaneous detection of distinct types of antibody-
secreting cells. J Immunol Methods;115:31-37. 
De Weck A.L., Sanz M.L., Gamboa P.M., Aberer W., Bienvenu J., Blanca M., Demoly P., Ebo 
D.G., Mayorga L., Monneret G. & Sainte-Laudy J. (2008). Diagnostic tests based on 
human basophils: more potentials and perspectives than pitfalls. Int Arch Allergy 
Immunol; 146: 177-89. 
De Weck A.L., Sanz M.L., Gamboa P.M., Aberer W., Bienvenu J., Blanca M., Demoly P., Ebo 
D.G., Mayorga L., Monneret G., Sainte Laudy J. (2008). Diagnostic tests based on 
human basophils: more potentials and perspectives than pitfalls. II. Technical 
issues. J Investig Allergol Clin Immunol; 18: 143-55. 
De Weck A.L., Sanz M.L., Gamboa P.M., Aberer W., Blanca M., Correia S., Erdman S., 
Jermann J.M., Kanny G., Kowalski M., Mayorga L., Medrala W., Merk A., Sturm 
G.J., Sainte-Laudy J., Schneider M.S., Sczczeklik A., Weber J.M. & Wedi A. (2009). 
Nonsteroidal anti-inflammatory drug hypersensitivity syndrome. A multicenter 
study. I. Clinical findings and in vitro diagnosis. J Investig Allergol Clin 
Immunol;19(5):355-69. 
De Weck A.L., Sanz M.L., Gamboa P.M., Jermann J.M., Kowalski M., Medrala W., Sainte-
Laudy J., Schneider M.S., Weber J.M. & Wolanczyk-Medrala A. (2010). 
Nonsteroidal anti-inflammatory drug hypersensitivity syndrome: a multicenter 
study. II. Basophil activation by nonsteroidal anti-inflammatory drugs and its 
impact on pathogenesis. J Investig Allergol Clin Immunol;20(1):39-57. 
www.intechopen.com
 
Drug Hypersensitivity 273 
Ebo D.G., Piel G.C., Conraads V. & Stevens W.J. (2001). IgE-mediated anaphylaxis after first 
intravenous infusion of cyclosporine. Ann Allergy Asthma Immunol; 87:243-245. 
Ebo D.G., Lechkar B., Schuerwegh A.J., Bridts C.H., De Clerck L.S., Stevens W.J. (2002). 
Validation of a two-color flow cytometric assay detecting in vitro basophil 
activation for the diagnosis of IgE mediated natural rubber latex allergy. Allergy; 57: 
706-12. 
Ebo D.G., Haine S.E., Hagendorens M.M., Bridts C.H., Conraads V.M., Vorlat A., Vrints C.J., 
De Clerck L.S. & Stevens W.J. (2004). Hypersensitivity to nadroparin calcium: case 
report and review of the literature. Clin Drug Investig; 24:421-426. 
Ebo D.G., Hagendorens M.M., Bridts C.H., Schuerwegh A.J., De Clerk L.D. & Stevens W.J. 
(2004). In vitro allergy diagnosis: should we follow the flow? Clin Exp Allergy; 34: 
332-9. 
Ebo D.G., Goossens S., Opsomer F., Bridts C.H. & Stevens W.J. Flow-assisted diagnosis of 
anaphylaxis to hyaluronidase. (2005). Allergy; 60:1333-1334. 
Ebo D.G., Sainte-Laudy J., Bridts C.H., Mertens C.H., Hagendorens M.M., Schuerwegh A.J., 
De Clerck L.S. & Stevens W.J. (2006). Assisted allergy diagnosis: current 
applications and future perspectives. Allergy; 61: 1028-39. 
Ebo D.G., Bridts C.H., Hagendorens M.M., Mertens C.H., De Clerck L.S. & Stevens W.J. 
(2006). Flow-assisted diagnostic management of anaphylaxis from rocuronium 
bromide. Allergy; 61: 935–9. 
Ebo D.G., Bridts C.H. & Stevens W.J. IgE-mediated anaphylaxis from chlorhexidine: 
diagnostic possibilities. (2006). Contact Dermatitis; 55:301-302.  
Fernandez T.D., Mayorga C., Torres M.J., Cornejo-Garcia J.A., López S., Chaves P., Rondon 
C. & Blanca M. (2008). Cytokine and chemokine expression in the skin from 
patients with maculopapular exanthema to drugs. Allergy; 63:712-719. 
Fernández T.D., Canto G. & Blanca M. Molecular mechanisms of maculopapular exanthema. 
Curr Opin Infect Dis. 2009 Jun;22(3):272-8. 
Fernandez T.D., Torres M.J., Lopez S., Antunez C., Gomez E., Del Prado M.F., Canto G., 
Blanca M. & Mayorga C. (2010). Role of effector cells (CCR7-CD27-) and effector-
memory cells (CCR7-CD27+) in drug-induced maculopapular exanthema. Int J 
Immunopathol Pharmacol;23:437-447. 
Gamboa P.M., Sanz M.L., Caballero M.R., Antépara I., Urrutia I., Jáuregui I., González G., 
Diéguez I. & De Weck A.L. (2003). Use of CD63 expression as a marker of in vitro 
basophil activation and leukotriene determination in metamizol allergic patients. 
Allergy 2003; 58: 312-7. 
Gamboa P.M., Sanz M.L., Urrutia I., Jáuregui I., Antépara I., Diéguez I. & De Weck A.L. 
(2003). CD63 expression by flow cytometry in the in vitro diagnosis of allergy to 
omeprazole. Allergy; 58:538-539. 
Gamboa P, Sanz ML, Caballero MR, Urrutia I, Antépara I, Esparza R, de Weck AL. (2004). 
The flow-cytometric determination of basophil activation induced by aspirin and 
other non-steroidal antiinflammatory drugs (NSAIDs) is useful for in vitro 
diagnosis of the NSAID hypersensitivity syndrome. Clin Exp Allergy; 34: 1448-57. 
Gamboa P.M., García-Avilés M.C., Urrutia I., Antépara I., Esparza R. & Sanz M.L. (2004). 
Basophil activation and sulfidoleukotriene production in patients with immediate 




Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 274 
Gómez E., Blanca-Lopez N., Torres M.J., Requena G., Rondon C., Canto G., Blanca M. & 
Mayorga C. (2009). IgE- mediated immediate allergic reactions to dipyrone: value 
of basophil activation test in the identification of patients. Clin Exp 
Allergy;39(8):1217-24. 
Hausmann O.V., Gentinetta T., Bridts C.H. & Ebo D.G. (2009). The Basophil Activation Test 
in Immediate-Type Drug Allergy. Immunol Allergy Clin North Am; 29 :555-566. 
Hertl M., Geisel J., Boecker C. & Merk H.F. (1993). Selective generation of CD81 T-cell clones 
from the peripheral blood of patients with cutaneous reactions to beta-lactam 
antibiotics. Br J Dermatol ;128(6):619–26. 
Kano Y., Hirahara K., Mitsuyama Y., Takahashi R. & Shiohara T. (2007). Utility of the 
lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on 
its timing and the type of drug eruption. Allergy;62:1439-1444. 
Kleine-Tebbe J., Erdmann S., Knol E.F., Macglashan D.W. Jr, Poulsen K.L. & Gibbs BF. 
(2006). Diagnostic tests based on human basophils: potentials, pitfalls and 
perspectives. Int Arch Allergy Immunol; 141: 79-90. 
Kvedariene V., Kamey S., Ryckwaert Y., Rongier M., Bousquet J., Demoly P. & Arnoux B. 
(2006). Diagnosis of neuromuscular blocking agent hypersensitivity reactions using 
cytofluorimetric analysis of basophils. Allergy; 61:311–315. 
Laxenaire M.C., and the perioperative anaphylactic reactions study group. (1999). 
Epidemiology of anesthetic anaphylactoid reactions. Fourth multicentric survey. 
Ann. Fr Anesth Reanim; 18:796–809. 
Lehmann S. & Ott H. (2008). Glucocorticoid hypersensitivity as a rare but potentially fatal 
side effect of paediatric asthma treatment: a case report. J Med Case Report; 2:186. 
Le Pabic F., Sainte-Laudy J., Blanchard N. & Moneret-Vautrin D.A. (2003). First case of 
anaphylaxis to iodinated povidone. Allergy; 58:826-827.  
Lerch M., Keller M., Britschgi M., Kanny G., Tache V., Schmid D.A., Beeler A., Gerber B.O., 
Luethi M., Bircher A.J., Christiansen C. & Pichler W.J. (2007). Cross-reactivity 
patterns of T cells specific for iodinated contrast media. J Allergy Clin 
Immunol;119(6):1529–36. 
Leyva L., Torres M.J., Posadas S., Blanca M., Besso G., O'Valle F., del Moral R.G., Santamaría 
L.F. & Juárez C. (2000). Anticonvulsant-induced toxic epidermal necrolysis: 
monitoring the immunologic response. J Allergy Clin Immunol; 105:157-165 
Leysen J., Bridts C.H., De Clerck L.S., Vercauteren M., Lambert J., Weyler J.J., Stevens W.J. & 
Ebo D.G. (2011). Allergy to rocuronium: from clinical suspicion to correct 
Diagnosis. Allergy; DOI:10.1111/j.1398-9995.2011.02569 
Lopez S., Torres M.J., Rodríguez-Pena R., Blanca-Lopez N., Fernandez T.D., Antunez C., 
Canto G., de Luque V. & Mayorga C. (2009). Lymphocyte proliferation response in 
patients with delayed hypersensitivity reactions to heparins. Br J Dermatol; 160:259-
65. 
Lopez S., Torres M.J., Antunez C., Rodríguez-Pena R., Canto G., Blanca M. & Mayorga C. 
(2010). Specific immunological response to budesonide in a patient with delayed-
type hypersensitivity reaction. J Invest Dermatol; 130(3):895-7.  
Luque I., Leyva L., José Torres M., Rosal M., Mayorga C., Segura J.M., Blanca M. & Juárez C. 
(2001). In vitro T-cell responses to beta-lactam drugs in immediate and 
nonimmediate allergic reactions. Allergy; 56:611-8.  
www.intechopen.com
 
Drug Hypersensitivity 275 
Mauri-Hellweg D., Bettens F., Mauri D., Brander C., Hunziker T. & Pichler W.J. (1995). 
Activation of drug-specific CD41 and CD81 T cells in individuals allergic to 
sulfonamides, phenytoin, and carbamazepine. J Immunol; 155(1):462– 72. 
Mayorga C., Torres M.J., Corzo J.L., Sanchez-Sabate E., Alvarez J., Vera A., Posadas S., 
Jurado A. & Blanca M. (2003). Improvement of toxic epidermal necrolysis after the 
early administration of a single high dose of intravenous immunoglobulin. Ann 
Allergy Asthma Immunol; 91:86–91. 
Mayorga C., Pena R.R., Blanca-López N., López S., Martin E. & Torres M.J. (2006). 
Monitoring the acute phase response in non-immediate allergic drug reactions. 
Curr Opin Allergy Clin Immunol;6:249-57. 
Monneret G., Benoit Y., Debard A.L., Gutowski M.C., Topenot I. & Bienvenu J. (2002). 
Monitoring of basophil activation using CD63 and CCR3 in allergy to muscle 
relaxant drugs. Clin Immunol; 102 :192-9. 
Moss J. (1995). Muscle relaxants and histamine release. Acta Anaesthesiol Scand; 39(S106):7-12. 
Orta M., Ordoqui E., Aranzábal A., Fernández C., Bartolomé B. & Sanz M.L. (2003). 
Anaphylactic reaction after artificial insemination. Ann Allergy Asthma Immunol; 
90:446-451. 
Mullen A.C., High F.A., Hutchins A.S., Lee H.W., Villarino A.V., Livingston D.M., Kung 
A.L., Cereb N., Yao T.P., Yang S.Y. & Reiner S.L. (2001). Role of T-bet in 
commitment of Th1cells before IL-12-dependent selection. Science; 292:1907–1910. 
Naisbitt D.J., Farrell J., Wong G., Depta J.P., Dodd C.C., Hopkins J.E., Gibney C.A., 
Chadwick D.W., Pichler W.J., Pirmohamed M., & Park B.K. (2003). Characterization 
of Skin Homing Lamotrigine-specific T-cells from hypersensitive patients. J Allergy 
Clin Immunol; 111:1393–1403. 
Naisbitt D.J., Britschgi M., Wong G., Farrell J., Depta J.P., Chadwick D.W., Pichler W.J., 
Pirmohamed M. & Park B.K. (2003). Hypersensitivity reactions to carbamazepine: 
characterization of the specificity, phenotype, and cytokine profile of drug-specific 
T-cell clones. Mol Pharmacol; 63:732–741. 
Nassif A., Bensussan A., Dorothée G., Mami-Chouaib F., Bachot N., Bagot M., Boumsell L., 
Roujeau J.C. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic 
epidermal necrolysis. J Invest Dermatol 2002; 118:728- 733. 
Nassif A., Bensussan A., Boumsell L., Deniaud A., Moslehi H., Wolkenstein P., Bagot M., & 
Roujeau J.C. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T 
cells. J Allergy Clin Immunol 2004; 114:1209-1215. 
Nassif A., Moslehi H., Le Gouvello S., Bagot M., Lyonnet L., Michel L., Boumsell L., 
Bensussan A. & Roujeau J.C. (2004). Evaluation of the potential role of cytokines in 
Toxic Epidermal Necrolysis. J Invest Dermatol; 123:850-855. 
Nishio D., Izu K., Kabashima K. & Tokura Y. (2007). T cell populations propagating in the 
peripheral blood of patients with drug eruptions. J Dermatol Sci; 48:25-33. 
Nyfeler B. & Pichler W.J. (1997). The lymphocyte transformation test for the diagnosis of 
drug allergy: sensitivity and specificity. Clin Exp Allergy; 27:175–181. 
Padial M.A., Alvarez-Ferreira J., Tapia B., Blanco R., Mañas C., Blanca M. & Bellón T. (2004). 




Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 276 
Pâris-Köhler A., Demoly P., Persi L., Lebel B., Bousquet J. & Arnoux B. (2000). In vitro 
diagnosis of cypress pollen allergy by using cytofluorometric analysis of basophils 
(Basotest). J Allergy Clin Immunol; 105: 339-45. 
Pichler W.J. (2003). Delayed drug hypersensitivity reactions. Ann Intern Med; 139:683-693. 
Pichler W.J. & Tilch J. (2004). The lymphocyte transformation test in the diagnosis of drug 
hypersensitivity. Allergy; 59:809-20.  
Pinnobphun P., Buranapraditkun S., Kampitak T., Hirankarn N. & Klaewsongkram J. (2011). 
The diagnostic value of basophil activation test in patients with an immediate 
hypersensitivity reaction to radiocontrast media. Ann Allergy Asthma 
Immunol;106(5):387-93. 
Posadas S.J., Leyva L., Torres M.J., Rodriguez J.L., Bravo I., Rosal M., Fernandez J., Juarez C. 
& Blanca M. (2000). Subjects with allergic reactions to drugs show polarized 
patterns of cytokine expression depending on the chronology of the clinical 
reaction. J Allergy Clin Immunol; 106:769-776. 
Posadas S.J., Padial A., Torres M.J., Mayorga C., Leyva L., Sanchez E., Alvarez J., Romano 
A., Juarez C. & Blanca M. (2002). Delayed reactions to drugs show a Th1 profile and 
levels of perforin, granzyme B and Fas-L related to disease severity. J Allergy Clin 
Immunol; 109:155–161. 
Rengarajan J., Szabo S.J. & Glimcher LH. (2000). Transcriptional regulation of Th1/Th2 
polarization. Immunol Today; 21:479–483. 
Rodriguez-Pena R., Lopez S., Mayorga C., Antunez C., Fernandez T.D., Torres M.J. & Blanca 
M. (2006). Potential involvement of dendritic cells in delayed-type hypersensitivity 
reactions to beta-lactams. J Allergy Clin Immunol; 118:949-56. 
Rodríguez Trabado A., Cámara Hijón C., Porcel Carreño S.L., Rodríguez Martín E., Fletes 
Peral C., Pereira Navarro G., Jiménez Timón S., Hernández Arbeiza F.J. & 
Fernández Pereira L. (2006). Anaphylaxis caused by cloxacillin: diagnosis with 
seriated analysis by way of basophil activation test. Allergy Asthma Proc; 27:269-72.  
Rodríguez-Trabado A., Cámara-Hijón C., Ramos-Cantariño A., Porcel-Carreño S.L., 
Jiménez-Timón S., Pereira-Navarro G., Hernández-Arbeiza F.J. & Fernández-
Pereira L. 2008. Basophil activation test for the in vitro diagnosis of nonsteroidal 
anti-inflammatory drug hypersensitivity. Allergy Asthma Proc; 29:241-9. 
Romano A., Torres M.J., Castells M. & Sanz M.L. (2011). Diagnosis and management of drug 
hypersensitivity reactions. J Allergy Clin Immunol;127:S67-73. 
Romano A., Torres M.J., Castells M., Sanz M.L. & Blanca M. (2011). Diagnosis and 
management of drug hypersensitivity reactions. J Allergy Clin Immunol;127:67-73. 
Roujeau J.C., Albengres E. & Moritz S. (1985). Lymphocyte transformation test in drug 
induced toxic epidermal necrolysis. Int Arch Allergy Appl Immunol;78:22–4.  
Rozieres A., Vocanson M., Nosbaum A., Cuerq C., Rouzaire P. & Ben Saïd B. (2009). Role of 
T cells in non-immediate allergic drug reaction. Current Op Allergy Clin 
Immunol;9(4):305-10. 
Rozieres A., Hennino A., Rodet K., Gutowski M.-C., Gunera-Saad N., Berard F., Cozon G., 
Bienvenu J. & Nicolas J.-F. (1997). Detection and quantification of drug-specific T 
cells in penicillin allergy. Allergy; 64: 534–542. 
Sabbah A., Sainte-Laudy J., Drouet M., Lauret M.G. & Loiry M. (1997). Anaphylactic or 




Drug Hypersensitivity 277 
Sabbah A., Plassais R., Grenapin S., Drouet M., Lauret M.G., Loiry M. & Sainte-Laudy J. 
(1998). Testing basophil activation by flow cytometry in the diagnosis of allergy to 
hymenopteran venom. Allerg Immunol (Paris); 30: 44- 8. 
Sainte-Laudy J., Sabbah A., Drouet M., Lauret M.G. & Loiri M. (2000). Diagnosis of venom 
allergy by flow cytometry. Correlation with clinical history, skin tests, specific IgE, 
histamine and leukotriene C4 release. Clin Exp Allergy; ; 30: 1166-71 
Sanz M.L., Sánchez G., Gamboa P.M., Vila L., Uasuf C., Chazot M., Diéguez I. & De Weck 
A.L. (2001). Ag-induced basophil activation: CD63 cell expression detected by flow 
cytometry in patients allergic to Dermatophagoides pteronyssinus and Lolium 
perenne. Clin Exp Allergy; 31: 1007-13. 
Sanz M.L., De Weck A.L., Uasuf C., Gamboa P.M. & Chazot M. (2001). Use of flow 
cytometry to assess basophil activation in patients allergic to betalactam antibiotics. 
Correlation between Flow cytometric Alergen Stimulation Test (FAST) and other in 
vivo and in vitro tests. Int Arch Allergy Immunol, 124: 307-8. 
Sanz M.L., Gamboa P.M., Antépara I., Uasuf C., Vila L., Garcia-Avilés C., Chazot M., & De 
Weck AL. (2002). Flow- cytometric basophil activation test by detection of CD63 
expression in patients with immedate type reactions to Betalactam antibiotics. Clin 
Exp Allergy; 32: 277-86. 
Sanz M.L., Maselli J.P., Gamboa P.M., Oehling A., Diéguez I. & de Weck A.L. (2002). 
Diagnosis and management of drug hypersensitivity. J Invest Allergol Clin Immunol; 
12:143-54. 
Sanz M.L., Gamboa P.M., García-Avilés C., Vila L., Diéguez I., Antépara I., de Weck A.L. 
(2003). Flow-cytometric cellular allergen stimulation test in latex allergy. Int Arch 
Allergy Immunol; 130: 33-9. 
Sanz M.L., Gamboa P.M. & De Weck A.L. (2005). A new combined test with flowcytometric 
basophil activation and determination of sulfidoleukotrienes is useful for in vitro 
diagnosis of hypersensitivity to aspirin and other nonsteroidal anti- inflammatory 
drugs. Int Arch Allergy Immunol; 136: 58-72. 
Sanz M.L., Gamboa P.M. & De Weck A.L. (2008). Cellular test in the diagnosis of drug 
hypersensitivity. Curr Pharml Des, 14: 2803-2808. 
Sanz M.L., Gamboa P.M. & Mayorga C. (2009). Basophil activation tests in the evaluation of 
immediate drug hypersensitivity. Curr Opin Allergy Clin Immunol; 9: 298-304 
Saporta M., Kamei S., Persi L., Bousquet J. & Arnoux B. (2001). Basophil activation during 
pollen season in patients monosensitized to grass pollens. Allergy; 56: 442-5 
Schleimer R.P., Fox C.C., Togias A., Norman P. & Lichtenstein LM. (1985). Role of human 
basophils and mast cells in the pathogenesis of allergic diseases. J Allergy Clin 
Immunol; 76, 369-74. 
Schmittel A., Keilholz U. & Scheibenbogen C. (1997). Evaluation of the interferon-gamma 
ELISPOT-assay for quantification of peptide specific T lymphocytes from 
peripheral blood. J Immunol Methods;210:167-174. 
Schmittel A., Keilholz U., Bauer S., Kuhne U., Stevanovic S., Thiel E. & Scheibenbogen C. 
(2001). Application of the IFN- gamma ELISPOT assay to quantify T cell responses 
against proteins. J Immunol Methods;247:17-24. 
Schnyder B., Burkhart C., Schnyder-Frutig K., von Greyerz S., Naisbitt D.J., Pirmohamed M., 
Park B.K. & Pichler W.J. . (2000). Recognition of sulfamethoxazole and its reactive 
www.intechopen.com
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 278 
metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol; 
164:6647-6654. 
Schnyder B. & Pichler W.J. (2000). Skin and laboratory tests in amoxicillin- and penicillin-
induced morbilliform skin eruption. Clin Exp Allergy; 30: 590–595. 
Shiohara T. & Mizukawa Y. (2007). Fixed drug eruption: a disease mediated by self-inflicted 
responses of intraepidermal T cells. Eur J Dermatol;17(3):201-8.  
Sudheer P.S., Hall J.E., Read G.F., Rowbottom A.W. & Williams PE. (2005). Flow cytometric 
investigation of peri- anaesthetic anaphylaxis using CD63 and CD203c. Anaesthesia; 
60:251–256. 
Stellato C., de Paulis A., Cirillo R., Mastronardi P., Mazzarella B. & Marone G. (1991). 
Heterogeneity of human mast cells and basophils in response to muscle relaxants. 
Anesthesiology; 74:1078-86. 
Tapia B., Padial A., Sanchez-Sabate E., Alvarez-Ferreira J., Morel E., Blanca M. & Bellon T. 
(2004). Involvement of CCL27- CCR10 interactions in drug-induced cutaneous 
reactions. J Allergy Clin Immunol ;114:335-340. 
Torres M.J., Padial A, Mayorga C., Fernandez T., Sanchez-Sebate E., Cornejo-Garcia J.A., 
Antúnez C. & Blanca M. (2004). The diagnostic interpretation of basophil activation 
test in immediate allergic reactions to betalactams. Clin Exp Allergy; 34: 1768-75. 
Torres M.J., Mayorga C., Fernández T.D., Cornejo-García J.A., Antúnez C., Valenzuela M., 
Del Prado M.F., Rodriguez- Pena R. & Blanca M. (2006). T cell assessment in 
allergic drug reactions during the acute phase according to the time of occurrence. 
Int J Immunopathol Pharmacol; 19(1):119-30.  
Torres M.J., Mayorga C., Cornejo-Garcia J.A., Lopez S., Chaves P., Rondon C., Fernandez T. 
& Blanca M. (2008). Monitoring non-immediate allergic reactions to iodine contrast 
media. Clin Exp Immunol; 152:233-238.  
Torres M.J., Mayorga C. & Blanca M. (2009). Nonimmediate allergic reactions induced by 
drugs: Pathogenesis and diagnostic tests. J Investig Allergol Clin Immunol; 19: 80-90. 
Whittam L.R., Wakelin S.H. & Barker JNWN. (2000). Generalized pustular psoriasis or drug-
induced pustuloderma? The use of patch testing. Clin Exp Dermatol; 25: 122-124. 
Yawalkar N., Shrikhande M., Hari Y., Nievergelt H., Braathen L.R. & Pichler WJ. (2000). 
Evidence for a role of IL-5 and eotaxin in activating and recruitment of eosinophils 
in drug-induced cutaneous eruptions. J Allergy Clin Immunol; 106:1171-6. 
Zawodniak A., Lochmatter P., Yerly D., Kawabata T., Lerch M., Yawalkar N. & Pichler WJ. 
(2010). In vitro detection of cytotoxic T and NK cells in peripheral blood of patients 
with various drug-induced skin diseases. Allergy;65:376- 384. 
Zedlitz S., Linzbach L., Kaufmann R. & Boehncke W.H. (2002). Reproducible identification 
of the causative drug of a fixed drug eruption by oral provocation and lesional 
patch testing. Contact Dermatitis; 46: 352-353. 
www.intechopen.com
Allergic Diseases - Highlights in the Clinic, Mechanisms and
Treatment
Edited by Prof. Celso Pereira
ISBN 978-953-51-0227-4
Hard cover, 554 pages
Publisher InTech
Published online 14, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The present Edition "Allergic diseases - highlights in the clinic, mechanisms and treatment" aims to present
some recent aspects related to one of the most prevalent daily clinical expression disease. The effort of a
group of outstanding experts from many countries reflects a set of scientific studies very promising for a better
clinical care and also to the treatment and control of the allergy. This book provides a valuable reference text
in several topics of the clinical allergy and basic issues related to the immune system response. The
inflammatory reaction understanding in allergic disease is clearly evidenced, as well as new strategies for
further researches.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
María L. Sanz, Cristobalina Mayorga, Ruben Martínez-Aranguren and Pedro M. Gamboa (2012). Drug
Hypersensitivity, Allergic Diseases - Highlights in the Clinic, Mechanisms and Treatment, Prof. Celso Pereira
(Ed.), ISBN: 978-953-51-0227-4, InTech, Available from: http://www.intechopen.com/books/allergic-diseases-
highlights-in-the-clinic-mechanisms-and-treatment/cellular-tests-in-the-diagnosis-of-drug-hypersensitivity
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
